Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "MP"

10672 News Found

KIMS Hospital Bengaluru commences operations at PES University campus
Hospitals | December 16, 2025

KIMS Hospital Bengaluru commences operations at PES University campus

The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital


Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully
Drug Approval | December 15, 2025

Caplin Point Laboratories’ injectables facility completes INVIMA audit successfully

This is also an important milestone in our product strategy for our expansion into the larger Latin American market


FDA completes inspection of SMS Pharma’s Vizag facility
Drug Approval | December 14, 2025

FDA completes inspection of SMS Pharma’s Vizag facility

The inspection concluded with one minor observation in Form 483


Bristol Myers Squibb scores FDA priority review for Opdivo in advanced hodgkin lymphoma
Drug Approval | December 12, 2025

Bristol Myers Squibb scores FDA priority review for Opdivo in advanced hodgkin lymphoma

The FDA aims to make a decision by April 8, 2026


Bristol Myers Squibb unveils breakthrough Lymphoma data
News | December 11, 2025

Bristol Myers Squibb unveils breakthrough Lymphoma data

Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas


Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
interviews | December 10, 2025

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines


Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
interviews | December 10, 2025

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines


Novo Nordisk completes acquisition of Akero Therapeutics
News | December 10, 2025

Novo Nordisk completes acquisition of Akero Therapeutics

Akero became a wholly owned subsidiary of Novo Nordisk


Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications
News | December 10, 2025

Zydus launches affordable biosimilar 'Zyrifa' for cancer-related bone complications

Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors


Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
Clinical Trials | December 09, 2025

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma